Shrimp Disease Diagnostics Market - Global Forecast 2025-2032

The Shrimp Disease Diagnostics Market is seeing robust change as aquaculture producers, diagnostics firms, and research organizations work to mitigate disease risks and optimize seafood supply chains. Senior decision-makers navigating this sector must keep pace with technological shifts, regulatory trends, and evolving market strategies.

Market Snapshot: Growth and Strategic Landscape in Shrimp Disease Diagnostics

The global shrimp disease diagnostics market grew from USD 478.10 million in 2024 to USD 517.54 million in 2025 and is projected to reach USD 894.80 million by 2032, reflecting a CAGR of 8.14%. Market developments are fueled by innovations in molecular diagnostics, increased regulatory oversight, and a broader industry shift toward preventative health management. As field diagnostics and laboratory-based approaches converge, organizations are seeking agile testing solutions, end-to-end assay platforms, and data-driven surveillance capabilities to address both operational and strategic challenges within aquaculture health management.

Scope & Segmentation: Comprehensive Market Coverage

• Technology: Enzyme Linked Immunosorbent Assay, Loop Mediated Isothermal Amplification, Next Generation Sequencing, Polymerase Chain Reaction (Multiplex PCR, Quantitative PCR, Reverse Transcription PCR)
• Diagnostic Method: Histopathological Diagnostics, Immunological Diagnostics (Enzyme Linked Immunosorbent Assay, Lateral Flow Immunoassay, Western Blot), Microbiological Diagnostics, Molecular Diagnostics
• Application: Monitoring, Outbreak Investigation, Research, Screening
• End User: Academic Institutions, Aquaculture Farms, Diagnostic Laboratories, Research Institutes
• Disease Type: Bacterial Diseases, Fungal Diseases, Parasitic Diseases, Viral Diseases
• Region: Americas (North America—United States, Canada, Mexico; Latin America—Brazil, Argentina, Chile, Colombia, Peru), Europe, Middle East & Africa (Europe—United Kingdom, Germany, France, Russia, Italy, Spain, Netherlands, Sweden, Poland, Switzerland; Middle East—United Arab Emirates, Saudi Arabia, Qatar, Turkey, Israel; Africa—South Africa, Nigeria, Egypt, Kenya), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Malaysia, Singapore, Taiwan)
• Key Companies: Thermo Fisher Scientific, Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd, Abbott Laboratories, PerkinElmer, Inc., QIAGEN N.V., Bio-Rad Laboratories, Inc., Zoetis Inc., Merck & Co., Inc., Ceva Santé Animale S.A.

Shrimp Disease Diagnostics Market: Key Takeaways for Senior Leadership

• Advanced molecular tools and rapid on-site testing are replacing conventional approaches, driving operational agility and early risk identification.
• Industry partnerships between research centers and diagnostics providers ensure that emerging assays undergo rigorous real-world validation.
• Rise in demand for customizable multiplex and portable diagnostic platforms is enabling smallholders and commercial farms to scale disease surveillance.
• Integration of digital traceability and analytics is allowing more transparent monitoring and regulatory compliance across the supply chain.
• Regional market maturity varies: established Americas and European markets focus on molecular and sequencing techniques, while emerging regions seek accessible, cost-effective solutions.
• Heavy and diverse pathogen burdens drive the adoption of tailored assays for accurate detection and timely aquaculture health management.

Tariff Impact: United States Regulatory Measures and Market Accessibility

Recent tariff changes in the United States are increasing input costs, encouraging diagnostic labs to seek alternative suppliers and push for local reagent manufacturing. These adjustments have made stakeholder collaborations more dynamic as industry players restructure procurement strategies and budget allocations. Export-driven producers and research organizations are navigating higher compliance outlays, leading to greater exploration of regional trade agreements that help manage disruptions in critical testing supplies.

Methodology & Data Sources

This report uses a mixed-methods approach, drawing on in-depth interviews with laboratory leaders, aquaculture operators, and technology developers. Extensive secondary research includes scientific journals, regulatory filings, and industry databases. Quantitative modeling triangulates survey data, shipment records, and import-export statistics. Competitive benchmarking clarifies product innovation and partnership trends for an evidence-based market view.

Why This Report Matters

• Enables decision-makers to benchmark strategy and technology adoption in a rapidly evolving diagnostics landscape.
• Identifies opportunity areas for regional expansion, innovation, and collaborative investment in aquaculture health solutions.
• Helps mitigate supply, compliance, and tariff risks by clarifying procurement and localization trends.

Conclusion

The shrimp disease diagnostics market continues to advance, underpinned by emerging technologies, regulatory shifts, and evolving stakeholder dynamics. Strategy built on innovation, adaptability, and collaboration will position organizations for long-term resilience and success in this complex market.

Additional Product Information:

• Purchase of this report includes 1 year online access with quarterly updates.
• This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.